Skip to main content

12-01-2014 | SGLT2 inhibitors | Review | Article

Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors: A Review of Their Basic and Clinical Pharmacology

Diabetes Therapy

Author: Sanjay Kalra

Publisher: Springer Healthcare


Sodium-glucose co-transporter-2 (SGLT2) inhibitors are a newly developed class of oral anti-diabetic drugs (OADs) with a unique mechanism of action. This review describes the biochemistry and physiology underlying the use of SGLT2 inhibitors, and their clinical pharmacology, including mechanism of action and posology. The pragmatic placement of these molecules in the existing OAD arena is also discussed.

Please log in to get access to this content

Related topics

CME-accredited webcast

Learn more about real-world evidence of new GLP-1RAs with Melanie Davies, Stewart Harris & Takashi Kadowaki

Image Credits